Of the 96 NSCLC sample pairs analyzed, we found that 18 patients (18.75%) were positively concordant; that is, KRAS G12/G13 mutations were detected in both cfDNA by ddPCR and in tumor tissues via Sanger sequencing. This evidence concerns the gene KRAS and neoplasm.